These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
350 related articles for article (PubMed ID: 29889414)
1. Links between genetics and immunology: mutations and antigens. Ayyoub M Bull Acad Natl Med; 2016 Jan; 200(1):67-79. PubMed ID: 29889414 [TBL] [Abstract][Full Text] [Related]
2. The role of neoantigens in response to immune checkpoint blockade. Riaz N; Morris L; Havel JJ; Makarov V; Desrichard A; Chan TA Int Immunol; 2016 Aug; 28(8):411-9. PubMed ID: 27048318 [TBL] [Abstract][Full Text] [Related]
3. Next generation approaches for tumor vaccination. Patel A; Kaufman HL; Disis ML Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672 [TBL] [Abstract][Full Text] [Related]
4. Neoantigens in cancer immunotherapy. Schumacher TN; Schreiber RD Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375 [TBL] [Abstract][Full Text] [Related]
5. Study May Change Approach to Immunotherapy. Cancer Discov; 2016 May; 6(5):OF1. PubMed ID: 27012834 [TBL] [Abstract][Full Text] [Related]
6. Cancer Neoantigens and Applications for Immunotherapy. Desrichard A; Snyder A; Chan TA Clin Cancer Res; 2016 Feb; 22(4):807-12. PubMed ID: 26515495 [TBL] [Abstract][Full Text] [Related]
7. Targeting neoantigens to augment antitumour immunity. Yarchoan M; Johnson BA; Lutz ER; Laheru DA; Jaffee EM Nat Rev Cancer; 2017 Apr; 17(4):209-222. PubMed ID: 28233802 [TBL] [Abstract][Full Text] [Related]
8. Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors. Leko V; Rosenberg SA Cancer Cell; 2020 Oct; 38(4):454-472. PubMed ID: 32822573 [TBL] [Abstract][Full Text] [Related]
9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors. Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255 [TBL] [Abstract][Full Text] [Related]
10. Targeting Neoantigens for Personalised Immunotherapy. Pritchard AL BioDrugs; 2018 Apr; 32(2):99-109. PubMed ID: 29516371 [TBL] [Abstract][Full Text] [Related]
11. Next-generation sequencing technologies accelerate advances in T-cell therapy for cancer. Yin Q; Tang J; Zhu X Brief Funct Genomics; 2019 Mar; 18(2):119-128. PubMed ID: 29982317 [TBL] [Abstract][Full Text] [Related]
12. The present status and future prospects of peptide-based cancer vaccines. Hirayama M; Nishimura Y Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694 [TBL] [Abstract][Full Text] [Related]
13. Personalized T cell-mediated cancer immunotherapy: progress and challenges. Bethune MT; Joglekar AV Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274 [TBL] [Abstract][Full Text] [Related]
14. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade? Furness AJ; Quezada SA; Peggs KS Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975 [No Abstract] [Full Text] [Related]
15. New emerging targets in cancer immunotherapy: the role of neoantigens. De Mattos-Arruda L; Blanco-Heredia J; Aguilar-Gurrieri C; Carrillo J; Blanco J ESMO Open; 2020 Apr; 4(Suppl 3):e000684. PubMed ID: 32269031 [TBL] [Abstract][Full Text] [Related]
16. Tumor neoantigens: building a framework for personalized cancer immunotherapy. Gubin MM; Artyomov MN; Mardis ER; Schreiber RD J Clin Invest; 2015 Sep; 125(9):3413-21. PubMed ID: 26258412 [TBL] [Abstract][Full Text] [Related]
17. T-cell cross-reactivity may explain the large variation in how cancer patients respond to checkpoint inhibitors. Sioud M Scand J Immunol; 2018 Mar; 87(3):. PubMed ID: 29381830 [TBL] [Abstract][Full Text] [Related]